Lupin concludes purchase of brands from Anglo-French

Written by Ruchika Sharma Published On 2022-04-07T14:38:45+05:30 | Updated On 7 April 2022 2:38 PM IST

Lupin concludes purchase of brands from Anglo-French

Mumbai: Global pharma major Lupin Limited has announced the completion of the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates.

"The acquisition will strengthen Lupin's India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India." the company said in a release.

"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we have already established ourselves as a leading provider of quality pharmaceuticals and a trusted partner. With this portfolio, Lupin will have a stronger market presence, providing healthcare professionals and patients with a more meaningful and comprehensive product offering," said Nilesh Gupta, Managing Director, Lupin.

"The portfolio sold to Lupin was birthed by Anglo-French, and now, through this divestiture, we are confident that these brands will scale to a significant size and have a large impact on the health and well-being of the Indian population. We are confident in Lupin's ability to enhance the value of our portfolio of brands," said Abhay Kanoria, Chairman & MD, AFDIL.

Shailesh Gadre, Founder of GCV Life was the exclusive advisor for the transaction.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

lupinlupin newsanglo-french drugs and industries

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751